Nair, Kavita V <br/><br/>
Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations.  [electronic resource] 

 -  Current medical research and opinion  Feb 2009 
 - 303-14 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-4877 
<br/><br/><label>Standard No.: </label>10.1185/03007990802598736  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antirheumatic Agents--administration & dosage<br/>Arthritis, Rheumatoid--drug therapy<br/>Cohort Studies<br/>Dose-Response Relationship, Drug<br/>Health Expenditures<br/>Health Services--statistics & numerical data<br/>Humans<br/>Infliximab<br/>Insurance, Health--classification<br/>Medicare<br/>Private Sector<br/>Retrospective Studies<br/>United States